



Use of Adjuvant Pharmacotherapy in Type 1 Diabetes: International Comparison of 49,367 Individuals in the Diabetes Prospective Follow-up and T1D Exchange Registries

<https://doi.org/10.2337/dc17-0403>

Sarah K. Lyons,¹ Julia M. Hermann,^{2,3}
Kellee M. Miller,⁴ Sabine E. Hofer,⁵
Nicole C. Foster,⁴
Birgit M. Rami-Merhar,⁶
Grazia Aleppo,⁷ Jochen Seufert,⁸
Linda A. DiMeglio,⁹ Thomas Danne,¹⁰
David M. Maahs,¹¹ and
Reinhard W. Holl^{2,3}

The majority of those with type 1 diabetes (T1D) have suboptimal glycemic control (1–4); therefore, use of adjunctive pharmacotherapy to improve control has been of clinical interest. While noninsulin medications approved for type 2 diabetes have been reported in T1D research and clinical practice (5), little is known about their frequency of use. The T1D Exchange (T1DX) registry in the U.S. and the Prospective Diabetes Follow-up (DPV) registry in Germany and Austria are two large consortia of diabetes centers; thus, they provide a rich data set to address this question.

For the analysis, 49,996 pediatric and adult patients with diabetes duration ≥ 1 year and a registry update from 1 April 2015 to 1 July 2016 were included (19,298 individuals from 73 T1DX sites and 30,698 individuals from 354 DPV sites). Adjuvant medication use (metformin, glucagon-like peptide 1 [GLP-1] receptor agonists, dipeptidyl peptidase 4 [DPP-4] inhibitors, sodium–glucose cotransporter 2 [SGLT2] inhibitors, and other noninsulin diabetes medications

including pramlintide) was extracted from participant medical records. The proportion using adjuvant medication was tabulated by registry and overall and stratified by medication class and age range. Logistic regression models to assess factors associated with adjuvant medication use were performed by registry. Linear regression was performed to assess the association between adjuvant medication use and HbA_{1c}, adjusting for age, sex, diabetes duration, ethnic/minority status, BMI, and total daily insulin.

The use of any adjuvant medication was 5.4% in T1DX and 1.6% in DPV ($P < 0.001$). Metformin was the most commonly reported medication in both registries, with 3.5% in the T1DX and 1.3% in the DPV ($P < 0.001$). For the T1DX, GLP-1 agonists were next (0.91%), followed by SGLT2 inhibitors (0.63%) and DPP-4 inhibitors (0.04%). In DPV, DPP-4 inhibitor use frequency was 0.13%, followed by that of SGLT2 inhibitors (0.13%) and GLP-1 agonists (0.07%). “Other” medications, which included pramlintide (T1DX only), sulfonylureas, and incretin therapy of

unknown type, were the third most common agents used in T1DX and second in DPV (0.86% and 0.21%, respectively). The frequency of adjuvant medication increased with age for combined registry data. However, when separated by registry, adjuvant use was highest in those aged 26 to < 50 years in the T1DX (12.1%) while it was highest in those aged ≥ 50 years in the DPV (7.0%) (Fig. 1). Use of adjuvant medication was associated with older age, higher BMI, and longer diabetes duration in both registries; female sex in T1DX only; and lower total daily insulin dose in DPV only (all $P < 0.001$). Mean \pm SD HbA_{1c} in those using and not using adjuvant medication was $8.4 \pm 1.7\%$ (68 ± 18 mmol/mol) vs. $8.5 \pm 1.7\%$ (69 ± 18 mmol/mol) in T1DX (adjusted $P = 0.04$) and $8.2 \pm 1.7\%$ (66 ± 18 mmol/mol) vs. $7.9 \pm 1.5\%$ (63 ± 16 mmol/mol) in DPV (adjusted $P < 0.001$).

Adjunctive agents, whose proposed benefits may include the ability to improve glycemic control, reduce insulin doses, promote weight loss, and suppress

¹Baylor College of Medicine, Houston, TX

²Institute of Epidemiology and Medical Biometry, ZIBMT, University of Ulm, Ulm, Germany

³German Center for Diabetes Research, Munich-Neuherberg, Germany

⁴Jaeb Center for Health Research, Tampa, FL

⁵Department of Pediatrics, Medical University of Innsbruck, Innsbruck, Austria

⁶Department of Pediatric and Adolescent Medicine, Medical University of Vienna, Vienna, Austria

⁷Northwestern University, Chicago, IL

⁸University Hospital Freiburg, Freiburg, Germany

⁹Indiana University School of Medicine, Indianapolis, IN

¹⁰Children's and Youth Hospital on the Bult, Hanover, Germany

¹¹Stanford University, Palo Alto, CA

Corresponding author: Kellee M. Miller, t1dstats1@jaeb.org.

Received 1 March 2017 and accepted 8 July 2017.

© 2017 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at <http://www.diabetesjournals.org/content/license>.




Figure 1—Use of adjuvant noninsulin medication by registry, stratified by age range. Solid white bar, metformin; solid black bar, DPP-4 inhibitor; horizontal striped bar, GLP-1 agonist; dotted bar, SGLT2 inhibitor; vertical striped bar, other.

dysregulated postprandial glucagon secretion, have had little penetrance as part of the daily medical regimen of those in the registries studied. Use of these agents was higher in the T1DX than in the DPV and more common in adults as compared with youth with T1D. Metformin was the most commonly reported medication; however, it is important to note that registry data did not capture the intent of adjuvant medications, which

may have been to treat polycystic ovarian syndrome in women. Further prospective study of the patterns of adjuvant pharmacotherapy use and the long-term impact on metabolic control is needed in patients with T1D.

Funding. The T1D Exchange is supported through the Leona M. and Harry B. Helmsley Charitable Trust. The DPV is supported through

the German Federal Ministry of Education and Research (BMBF) Competence Network Diabetes Mellitus (FKZ 01GI1106), which was integrated into the German Center for Diabetes Research (DZD) as of January 2015.

Duality of Interest. No potential conflicts of interest relevant to this article were reported.

Author Contributions. S.K.L. contributed to data interpretation and wrote and edited the article. J.M.H. performed statistical analysis and contributed to data interpretation. K.M.M., S.E.H., N.C.F., B.M.R.-M., G.A., J.S., L.A.D., T.D., D.M.M., and R.W.H. contributed to data interpretation and reviewed and edited the letter. R.W.H. is the guarantor of this work and, as such, had full access to all the data in the study and takes responsibility for the integrity of the data and accuracy of the data analysis.

References

1. Miller KM, Foster NC, Beck RW, et al.; T1D Exchange Clinic Network. Current state of type 1 diabetes treatment in the U.S.: updated data from the T1D Exchange clinic registry. *Diabetes Care* 2015;38:971–978
2. McKnight JA, Wild SH, Lamb MJ, et al. Glycaemic control of type 1 diabetes in clinical practice early in the 21st century: an international comparison. *Diabet Med* 2015;32:1036–1150
3. Maahs DM, Hermann JM, DuBose SN, et al.; DPV Initiative; T1D Exchange Clinic Network. Contrasting the clinical care and outcomes of 2,622 children with type 1 diabetes less than 6 years of age in the United States T1D Exchange and German/Austrian DPV registries. *Diabetologia* 2014;57:1578–1585
4. Weinstock RS, Schütz-Fuhrmann I, Connor CG, et al.; T1D Exchange Clinic Network; DPV Initiative. Type 1 diabetes in older adults: comparing treatments and chronic complications in the United States T1D Exchange and the German/Austrian DPV registries. *Diabetes Res Clin Pract* 2016;122:28–37
5. Frandsen CS, Dejgaard TF, Madsbad S. Non-insulin drugs to treat hyperglycaemia in type 1 diabetes mellitus. *Lancet Diabetes Endocrinol* 2016;4:766–780